Scarica l'app Stockscreener
2.25
2.27%
0.05
Dopo l'orario di chiusura:
2.25
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché EDIT Giù?
Forum
Previsione
Editas Medicine Inc Borsa (EDIT) Ultime notizie
Cancer Gene Therapy Market Set to Soar: Breakthrough - openPR.com
From Now to 2032: Unpacking the Genome Editing Market's - openPR.com
Editas Medicine Is Great. Here's Why You Shouldn't Buy It. - AOL.com
Editas Medicine Is Great. Here's Why You Shouldn't Buy It. - The Motley Fool
Analysts Set Editas Medicine, Inc. (NASDAQ:EDIT) Price Target at $5.36 - MarketBeat
Editas Medicine, Inc. (NASDAQ:EDIT) Position Trimmed by Bank of America Corp DE - MarketBeat
Analysts Offer Predictions for Editas Medicine FY2026 Earnings - MarketBeat
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Grows Stock Holdings in Editas Medicine, Inc. (NASDAQ:EDIT) - MarketBeat
Editas Medicine (EDIT) Unveils Promising Gene Editing Data for B - GuruFocus
Kalkine: Editas Medicine’s In Vivo Gene Editing Progress Unveiled at EHA 2025 with tLNP Approach - Kalkine Media
Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle - GuruFocus
Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hema - GuruFocus
Editas Medicine Reports 58% HBG1/2 Promoter Editing in Non-Human Primates Using High Efficiency tLNP Delivery Method - Nasdaq
Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology Association 2025 Congress in June - The Manila Times
Breakthrough: New Gene Editing Therapy Achieves 58% Success Rate for Sickle Cell Disease Treatment - Stock Titan
Why Is Editas (EDIT) Up 40% Since Last Earnings Report? - Yahoo Finance
Ameriprise Financial Inc. Has $289,000 Stake in Editas Medicine, Inc. (NASDAQ:EDIT) - MarketBeat
Editas Medicine, Inc. (NASDAQ:EDIT) CEO Sells $26,130.24 in Stock - MarketBeat
Zacks Research Raises Earnings Estimates for Editas Medicine - MarketBeat
Two Sigma Investments LP Increases Stake in Editas Medicine, Inc. (NASDAQ:EDIT) - MarketBeat
Millennium Management LLC Has $3.49 Million Stock Position in Editas Medicine, Inc. (NASDAQ:EDIT) - MarketBeat
Editas Medicine, Inc. (NASDAQ:EDIT) Short Interest Down 21.7% in May - MarketBeat
editas medicine amends stock plan and increases authorized shares - Investing.com
Editas Medicine Stockholders Approve Key Amendments - TipRanks
editas medicine amends stock plan and increases authorized shares By Investing.com - Investing.com India
Two Sigma Advisers LP Increases Holdings in Editas Medicine, Inc. (NASDAQ:EDIT) - MarketBeat
Top 5 CRISPR Companies To Invest In (June 2025) - Securities.io
Millennium Management LLC Cuts Stock Position in Editas Medicine, Inc. (NASDAQ:EDIT) - Defense World
Editas Medicine, Inc. (NASDAQ:EDIT) Shares Purchased by BNP Paribas Financial Markets - Defense World
Northern Trust Corp Has $884,000 Stock Holdings in Editas Medicine, Inc. (NASDAQ:EDIT) - Defense World
Brokerages Set Editas Medicine, Inc. (NASDAQ:EDIT) Price Target at $5.36 - MarketBeat
Editas Medicine (EDIT) Joins Russell Microcap Index - GuruFocus
Editas Medicine, Cassava Sciences among healthcare stocks to join Russell Microcap; MNKD, OCGN to exit - Seeking Alpha
CRISPR and Cas Genes Market Set to Witness Significant Growth - openPR.com
Editas Medicine’s SWOT analysis: gene editing stock pivots amid challenges By Investing.com - Investing.com Canada
Editas Medicine’s SWOT analysis: gene editing stock pivots amid challenges - Investing.com Australia
1 Stock Down 97% That Could Double, According to Wall Street - AOL.com
Tang Capital Management LLC Purchases Shares of 400,000 Editas Medicine, Inc. (NASDAQ:EDIT) - MarketBeat
Editas Medicine, Inc. (NASDAQ:EDIT) Given Consensus Rating of “Hold” by Brokerages - Defense World
Jacobs Levy Equity Management Inc. Has $900,000 Stock Holdings in Editas Medicine, Inc. (NASDAQ:EDIT) - MarketBeat
Editas Medicine, Inc.'s (NASDAQ:EDIT) Price Is Right But Growth Is Lacking After Shares Rocket 28% - simplywall.st
0.39%
0.42%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):